10.1371/journal.pone.0069619.g002
David J. Rickard
David
J. Rickard
Clark A. Sehon
Clark A.
Sehon
Viera Kasparcova
Viera
Kasparcova
Lorena A. Kallal
Lorena A.
Kallal
Xin Zeng
Xin
Zeng
Monica N. Montoute
Monica
N. Montoute
Tushar Chordia
Tushar
Chordia
Derek D. Poore
Derek
D. Poore
Hu Li
Hu
Li
Zining Wu
Zining
Wu
Patrick M. Eidam
Patrick M.
Eidam
Pamela A. Haile
Pamela A.
Haile
Jong Yu
Jong
Yu
John G. Emery
John
G. Emery
Robert W. Marquis
Robert W.
Marquis
Peter J. Gough
Peter J.
Gough
John Bertin
John
Bertin
GSK669 inhibits NOD2 but not NOD1 mediated responses.
Public Library of Science
2013
biotechnology
drug discovery
immunology
Immune system
cytokines
immunity
Immune activation
immunotherapy
inflammation
Innate immunity
autoimmunity
immunomodulation
Molecular cell biology
Signal transduction
Signaling pathways
chemical biology
medicinal chemistry
inhibits
nod2
nod1
mediated
2013-08-01 03:00:06
Figure
https://plos.figshare.com/articles/figure/_GSK669_inhibits_NOD2_but_not_NOD1_mediated_responses_/761930
<p>(A) Structure of GSK669, the original hit identified from the NOD2 HTS screening cascade. (B) Concentration response curves showing GSK669 selectively inhibits MDP-stimulated IL-8. IL-8 secretion in either MDP treated 293/hNOD2 or iE-DAP treated 293/hNOD1 stable cell lines was measured in the presence of increasing concentrations of GSK669. Data are mean ± SD from 6 independent assays. (C) Selective inhibition of NOD2-mediated MAPK phosphorylation by GSK669. Serum-starved 293/hNOD1 or NOD2 stable cells were pre-incubated with compound at the concentrations indicated and then stimulated for 1 hour with either Tri-DAP or MDP, respectively. Phospho-p38, JNK and ERK1/2 were identified in cell lysates by western blotting. A RIP2 inhibitor compound was used as a positive control. Similar results were obtained in 5 (293/hNOD2) and 2 (293/hNOD1) separate experiments.</p>